Home›Stocks›RARE

RARE — structural market context

Ultragenyx Pharmaceutical Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 15. Each line shows the earlier value, the later value and their dates.

Price

Close $15.17 (Oct 15) vs $14.90 (Oct 14): +1.81%.

Volume

0.56× its 20-session average (5.4M) on Oct 15.

Includes pre- and post-market trading.

Short interest

Short interest 20.3M shares (settlement Sep 30) vs 16.6M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 1–Sep 14, published Sep 30): 2 days with fails, largest 159K shares on Sep 3.

Previous file (settlements Aug 17–Aug 31, published Sep 16): 4 days with fails, largest 2K shares on Aug 24.

No new publication in this window.

Analyst rating actions

2 rating actions recorded.

UBS — Coverage initiated — Oct 14

UBS — Price target change — Oct 14

Insider filings (Form 4)

None recorded in this window.

RARE short interest & days to cover

SHARES SHORT
20.3M
% OF FLOAT
—
DAYS TO COVER
3.1
CHANGE VS PRIOR
+22.8%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (17d ago)

RARE fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-23 · 24d2K$15.62
2026-09-17 · 30d10K$12.88
2026-09-11 · 36d108$14.4

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

RARE insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 2 sales

InsiderTypeSharesValueFiled
Huizenga Theodore Alan · officer: SVP, Chief Accounting OfficerSell (S)1K$17K2026-09-15
Huizenga Theodore Alan · officer: SVP, Chief Accounting OfficerSell (S)161$2K2026-09-08

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

RARE analyst ratings

FirmActionRatingPublished
UBSinitialiseNeutral (from Buy)2026-10-14
UBSprice_target—2026-10-14
UBSholdBuy2026-09-25
H.C. WainwrightholdBuy2026-09-25
Evercore ISIprice_target—2026-09-21

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying RARE?
In the last 12 months of SEC Form 4 filings, RARE recorded 0 insider purchases and 2 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about RARE?
The most recent action: UBS initialise to Neutral on 2026-10-14. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell RARE?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with R

RCG · RENN Fund Inc.RELY · Remitly Global, Inc. Common StRGTI · Rigetti Computing, Inc. CommonRKLB · Rocket Lab Corporation CommonRMD · ResMed Inc.RMNI · Rimini Street, Inc. (DE) CommoAll R →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.